Trastuzumab Deruxtecan Showcases Clinical Efficacy in HER2+ Gynecological Cancers
Cancer Network,
“These data suggest that T-DXd is a potential treatment for patients with these gynecologic HER2-expressing tumors who have…
T-DXd Elicits Encouraging Clinical Benefits in HER2-Mutated Solid Tumors
Cancer Network,
"The DESTINY-PanTumor01 study showed clinically meaningful pan-tumor activity of T-DXd in patients with a broad range of…
Le trastuzumab Deruxtecan a une activité cliniquement significative dans les tumeurs solides hébergeant des mutations HER2
Nouvelles du monde,
Le fam-trastuzumab deruxtecan-nxki (Enhertu ; T-DXd) a suscité des réponses qui se sont révélées durables chez les patients prése…
Trastuzumab deruxtecan has clinically meaningful activity in solid tumors with HER2 mutations
NewsBeezer,
Fam-trastuzumab deruxtecan-nxki (Enhertu; T-DXd) produced responses that were shown to be durable in patients with a range of…